Scientific Program
Interactions with the environment
RESEARCH GROUP
Biotechnology of probiotics and intestinal pathogens
David Ruano Gallego
The digestive system is well-studied, but how it works during gut dysbiosis remains to be detailed, like during inflammation and infection processes. Especially as we are just starting to understand the role of key members of the microbiota. We aim to unravel pathogen-host interactions and develop bacteria-based strategies for gut diseases.
Research
The intestine plays a crucial role in our body, not only in absorbing nutrients from the food we eat but also in hosting a complex network of interactions involving intestinal enterocytes (cells lining the intestine), microbiome bacteria (microorganisms living in the gut), and the immune system. Changes in these factors can disrupt the stability of these interactions, allowing harmful bacteria to invade the intestine and cause diseases.
In our research laboratory, we focus on studying how pathogenic bacteria utilize a specialized mechanism called the Type 3 Secretion System to infect the intestine and evade the immune system’s defenses. These bacteria employ specific proteins known as effector proteins, which establish a network of interactions critical for their infection process. Our goal is to unravel this network of protein interactions to gain a better understanding of how infections occur and how the immune system responds to different infection strategies. To achieve this, we have created mutant strains of these pathogenic bacteria. We then use these mutants to infect mice and observe the effects they have on the intestine. This allows us to gain insights into the mechanisms behind infection and immunity.
Furthermore, we aim to harness the power of probiotics for biotechnological applications in the field of biomedicine. Using advanced techniques from synthetic biology, we intend to develop methods for manipulating strains of bacteria that were previously not well-understood. These particular bacterial strains have the potential to serve as indicators of good health and offer protection against intestinal diseases. Our research seeks to boost the capabilities of these probiotics as valuable tools for improving human health.
Group members
David Ruano Gallego
Lab.: 104 Ext.: 4678
druano(at)cbm.csic.es
Laura Gómez Ruiz
Lab.: 104 Ext.: 4678
laura.gomez(at)cbm.csic.es
Selected publications
Type III secretion system effectors form robust and flexible intracellular virulence networks
David Ruano-Gallego et al.
The type III secretion system effector network hypothesis
Julia Sanchez-Garrido et al.
A nanobody targeting the translocated intimin receptor inhibits the attachment of enterohemorrhagic E. coli to human colonic mucosa
David Ruano-Gallego et al
Screening and purification of nanobodies from E. coli culture supernatants using the hemolysin secretion system
David Ruano-Gallego et al.